Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. (Q50761215)

18 March 2018

title

Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. (English)

1 reference

18 March 2018

1 reference

Neri Pucci

1

1 reference

18 March 2018

Elio Novembre

2

1 reference

18 March 2018

Antonella Cianferoni

3

1 reference

18 March 2018

Enrico Lombardi

4

1 reference

18 March 2018

Roberto Bernardini

5

1 reference

18 March 2018

Roberto Caputo

6

1 reference

18 March 2018

Luciana Campa

7

1 reference

18 March 2018

Alberto Vierucci

8

1 reference

18 March 2018

publication date

1 September 2002

1 reference

18 March 2018

Annals of Allergy, Asthma & Immunology

published in

1 reference

18 March 2018

volume

89

1 reference

18 March 2018

issue

3

1 reference

18 March 2018

page(s)

298-303

1 reference

18 March 2018

Classification of ocular atopic/allergic disorders and conditions: an unsolved problem.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Vernal keratoconjunctivitis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Topical Cyclosporine in Vernal Keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Clinical Trial of Topical Disodium Chromoglycate in Vernal Keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

The use of cyclosporine in high-risk keratoplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Immunohistopathologic features and therapy of conjunctival lichen planus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Topical cyclosporin A in the treatment of anterior segment inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Topical cyclosporin A in the management of vernal keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Allergic and immunologic disorders of the eye. Part II: ocular allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

In vivo pharmacological effects of ciclosporin and some analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Conjunctival hyperresponsiveness to ocular histamaine challenge in patients with vernal conjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Prevalence and risk factors of latex sensitization in an unselected pediatric population.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961958-8

7 January 2021

10.1016/S1081-1206(10)61958-8

Identifiers

DOI

1 reference

18 March 2018

PubMed ID

12269651

1 reference

18 March 2018